Document is current
Any future updates will be listed below
-
Authors
Wang, Meihua https://orcid.org/0000-0002-8860-3329
Zhang, Xinghai
Li, Wujian
Yao, Yanfeng https://orcid.org/0000-0002-6175-8590
Li, Entao
Zhang, Baoyue
Zhou, Jinge https://orcid.org/0009-0000-2240-7870
Liu, Shunli
Gao, Yongxiang
Zhu, Zhongliang
Zhu, Lixia
Liu, Mengyao
Hu, Jing
Peng, Cheng
Li, Fangxu
Chen, Miaoyu
Liu, Hang
Yao, Chengbing
Shang, Yuhua
Yan, Feihu
Gong, Peng https://orcid.org/0000-0002-8264-7523
Jin, Tengchuan https://orcid.org/0000-0002-1395-188X
Chiu, Sandra https://orcid.org/0000-0001-9034-5755
- License Information
-
More Information
Article History
Received: 4 August 2025
Accepted: 19 February 2026
First Online: 17 March 2026
Competing interests
: T.C.T., M.H.W., S.C., and E.T.L. are named inventors on two patents covering the sequences of the 1A10 and BA2 nanobodies described in this study. These patents pertain to the use of said nanobodies for the prevention, treatment, or diagnosis of Ebola virus infection and impose no restrictions on data publication. All other authors declare no competing interests.
